All In Biotech

Drug Trial Radar · NCT00729937

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus Aureus ("STOP MRSA") - A Phase IIB, Multi-Center, Randomized, Double-Blind Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,265 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,265

Actual

Start

Apr 2009

Primary completion

May 2013

Study completion Jun 2013

Sponsor

Sponsor type
NIH
First posted
Aug 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal outpatient treatment strategy of uncomplicated skin and soft tissue infection (SSTI) in areas of the United States where the prevalence of Community-Acquired Methicillin-Resistant Staphylococcus (S.) aureus (CA-MRSA) is high. Infection with the S. aureus bacteria that is resistant to antibiotics is a cause of SSTIs. Three oral antibiotics will be tested for off patent treatment. Patients will receive Trimethoprim/Sulfamethoxazole (TMP/SMX), placebo (substance containing no medication), clindamycin, or cephalexin or some combination of these. The study population will include 2,235 volunteers, children 13 years of age and over and adults presenting to 5 large urban Emergency Departments. Therapy for acute uncomplicated SSTIs, including abscess, infected wound, and cellulitis will start on the day of enrollment. Participants may be involved in study related procedures for about 9 weeks.

Conditions

  • Staphylococcal Infection

Interventions

  • CephalexinDrug

    500 mg, four times per day.

  • ClindamycinDrug

    300 mg, four times per day.

  • PlaceboOther

    Placebo tablet administered orally.

  • Trimethoprim-sulfamethoxazoleDrug

    4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol PopulationTime frame: Days 14-21

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Maricopa Medical Center - Emergency Medicine

    Phoenix, Arizona

  • University of California Los Angeles - Olive View Medical Center

    Sylmar, California

  • Johns Hopkins University at Mount Washington - Emergency Medicine

    Baltimore, Maryland

  • Truman Medical Center - Hospital Hill

    Kansas City, Missouri

  • Temple University Hospital

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.